Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Free Newsletter Sign Up

AbbVie Bid to Block Humira Rival to Be Probed at Trade Agency

Jan. 26, 2022, 4:17 PM

The U.S. International Trade Commission has launched an investigation based on a complaint AbbVie filed seeking to block a biosimilar of its $20 billion-a-year arthritis drug Humira by Alvotech.

  • AbbVie also named Teva, which has agreed to sell the Iceland-made Alvotech copy, called AVT02, in the U.S. in a deal worth more than $450 million, according to the complaint
  • AbbVie said Alvotech recruited employees in Singapore to steal confidential information on the manufacturing process to create Humira, and continues efforts to poach AbbVie employees
  • Alvotech, which denies any theft, told the agency that an import ban would be against ...

To read the full article log in.

Learn more about a Bloomberg Law subscription